Chardan Capital Maintains Buy on SAB Biotherapeutics, Adjusts Price Target To $25 (reverse stock split 1:10)

-0.43% Pre

SAB Biotherapeutics Inc Ordinary Shares

SABS

0.00

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ: SABS) with a Buy, adjusts target to $25 from $3 (reverse stock split 1:10).

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

EUDA Health Holdings Limited's (NASDAQ:EUDA) biggest owners are retail investors who got richer after stock soared 28% last week

Lacklustre Performance Is Driving Bumble Inc.'s (NASDAQ:BMBL) 26% Price Drop

Evaluating BorgWarner (BWA): Is the Stock Still Undervalued After Recent Gains?

Assessing MRC Global (MRC) Valuation After Recent Share Price Decline and 2024 Performance

Class Action Lawsuits Over Pylarify Disclosures Could Be a Game Changer for Lantheus Holdings (LNTH)

Does Iridium Stock Deserve a Second Look After Its 38% Slide in 2024?

Did Slowing Organic Sales Just Shift Allegion's (ALLE) Investment Narrative?

Will Speculation Around U.S. Support Reshape TMC (TMC)’s Path to Critical Minerals Leadership?